Latest Industry Insights

Bio-Rad's Jeremiah McDole explores the benefits of bringing molecular testing in-house and how ddPCR technology can be applied in oncology workflows.

In this interview, James Brayer delves into some of the current obstacles hindering the widespread adoption of genomic medicine and highlights how nanopore-based sequencing can help to address them.

This article looks at the technologies currently being developed that can help to identify patients with a higher risk of prostate cancer, ultimately reducing the number of unnecessary biopsies.

A recent study has shown the clinical value of proactive, sequencing-based screening in apparently healthy newborns for medically actionable conditions. How might these findings impact the current NBS landscape and what does it mean to the healthcare system on the global level?

With growing sustainability demands, companies are looking for ways to demonstrate their green credentials. We spoke to Dr. Michael Frank to find out what ACT accreditation means for a company and why he thinks schemes like this are so important.

Robert Balog describes innovations in microarray testing technology that are contributing to faster turnaround times, automated interpretation and improved coverage.

HPLC system manufacturers have been striving to improve usability, accessibility and help users improve their experimental outcomes. And what better way to do that than to involve the users themselves in that development process.

Dr. Andreas Boehmler explores how the arrival of new flow cytometry platforms finally puts powerful automation within reach for many labs, allowing operators to enumerate stem cells more quickly and accurately for transplant.

We spoke with Bio-Rad’s Justin Barker to discover some of the challenges associated with gene expression analysis in oncology and learn about technology developments in this field.

Technology Networks had the pleasure of speaking with Dr. Maddison Masaeli, co-founder and chief executive officer at Deepcell to learn about the REM-I platform, a single-cell analysis tool that utilizes AI-powered imaging to magnify insights into a cell’s phenotype and function.